Effects of ulinastatin on therapeutic outcomes and inflammatory markers in pediatric septic shock patients.

This study aims to investigate the effects of ulinastatin on therapeutic outcomes and inflammatory markers in children with septic shock. This study selected 117 children with septic shock admitted to our hospital from April 2023 to April 2024. Among them, 7 children had comorbidities, 3 dropped out during the research process, 5 did not continue to participate in the study due to other reasons, and 4 explicitly refused to participate. After screening and excluding the above - mentioned cases, A total of 98 children were allotted to experimental group (ulinastatin combined with routine antishock therapy, n = 49) and control group (routine antishock therapy, n = 49) using stratified random method. The therapeutic effects and levels of inflammatory markers were assessed before and after treatment using a double antibody sandwich ELISA. The outcome was significantly better in the experimental group compared to controls (P < 0.05). Prior to treatment, there were no significant differences in the levels of CD64, procalcitonin (PCT), C-reactive protein, neutrophil-to-lymphocyte ratio (NLR), and serum α-hydroxybutyrate dehydrogenase between the two groups (all P > 0.05). After 7 days of treatment, the experimental group exhibited significantly lower levels of CD64, PCT, C-reactive protein, NLR, and serum α-hydroxybutyrate dehydrogenase compared to the control group (all P < 0.001). Ulinastatin enhances the therapeutic efficacy in children with septic shock by reducing levels of associated inflammatory markers and promoting recovery.